Hospital variation in intravenous inotrope use for patients hospitalized with heart failure insights from get with the guidelines

Circulation: Heart Failure

Volumn 7, Issue 2, 2014, Pages 251-260

  Allen, Larry A ^a   Fonarow, Gregg C ^b   Grau Sepulveda, Maria V ^c   Hernandez, Adrian F ^c   Peterson, Pamela N ^a,d   Partovian, Chohreh ^e,f,g   Li, Shu Xia ^e,f,g   Heidenreich, Paul A ^h   Bhatt, Deepak L ⁱ   Peterson, Eric D ^c   Krumholz, Harlan M ^e,f,g  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d Health Medical Center   (United States)

^e ROBERT WOOD JOHNSON FOUNDATION   (United States)

^f YALE UNIVERSITY   (United States)

^g YALE NEW HAVEN HOSPITAL   (United States)

^h Veterans Affairs Palo Alto Health Care System   (United States)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cardiotonic agents; Heart failure; Outcome and process assessment (health care); Physician's practice patterns

Indexed keywords

DOBUTAMINE; DOPAMINE; INOTROPIC AGENT; MILRINONE; CARDIOTONIC AGENT;

AGED; ARTICLE; COMBINATION CHEMOTHERAPY; DRUG PREFERENCE; FEMALE; HEART FAILURE; HOSPITAL CARE; HOSPITAL CHARGE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; VERY ELDERLY; CLINICAL PRACTICE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DOSE RESPONSE; FOLLOW UP; HOSPITAL; HOSPITAL PATIENT; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; REGISTER; RETROSPECTIVE STUDY; STANDARD; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

CARDIOTONIC AGENTS; HEART FAILURE; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PHYSICIAN'S PRACTICE PATTERNS;

AGED; CARDIOTONIC AGENTS; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GUIDELINE ADHERENCE; HEART FAILURE; HOSPITAL MORTALITY; HOSPITALS; HUMANS; INFUSIONS, INTRAVENOUS; INPATIENTS; LENGTH OF STAY; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PHYSICIAN'S PRACTICE PATTERNS; REGISTRIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; UNITED STATES;

EID: 84900033850     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.113.000761     Document Type: Article

References (21)

1. Yancy CW, Jessup M, Bozkurt B, Masoudi FA, Butler J, McBride PE, Casey Jr DE, McMurray JJV, Drazner MH, Mitchell JE, Fonarow GC, Peterson PN, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Riegel B, Sam F, Stevenson LW, Tang WHW, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the management of heart failure. Circulation. 2013;128:e240-e319
2. Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Katz SD, Klapholz M, Moser DK, Rogers JG, Starling RC, Stevenson WG, Tang WH, Teerlink JR, Walsh MN. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Cardiac Fail. 2010;16:e1-e194
3. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787-1847.
4. Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, Berkowitz RL, Galvao M, Horton DP; ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209-216.
5. Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, Gottlieb SO, McGrew F 3rd, DeMets DL, White BG. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med. 1998;339: 1810-1816.
6. Moran JF, Rad N, Scanlon PJ. Long term survival of class IV heart failure patients treated with oral amrinone. J Clin Pharmacol. 1989;29:494-499.
7. Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS, Massie BM, O'Connor CM, Pina I, Quigg R, Silver MA, Gheorghiade M; Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: A randomized controlled trial. JAMA. 2002;287:1541-1547.
8. Packer M. Randomized multicenter evaluation of intravenous levosimendan efficacy versus placebo in the short-term treatment of decompensated heart failure study (REVIVE-2). Paper presented at proceedings of the American Heart Association Scientific Sessions, Dallas, TX, November 13-16, 2005.
9. Goldhaber JI, Hamilton MA. Role of inotropic agents in the treatment of heart failure. Circulation. 2010;121:1655-1660.
10. Abraham WT, Adams KF, Fonarow GC, Costanzo MR, Berkowitz RL, LeJemtel TH, Cheng ML, Wynne J; ADHERE Scientific Advisory Committee and Investigators; ADHERE Study Group. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: An analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol. 2005;46:57-64.
11. Elkayam U, Tasissa G, Binanay C, Stevenson LW, Gheorghiade M, Warnica JW, Young JB, Rayburn BK, Rogers JG, DeMarco T, Leier CV. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am Heart J. 2007;153:98-104.
12. Partovian C, Gleim SR, Mody PS, Li SX, Wang H, Strait KM, Allen LA, Lagu T, Normand SL, Krumholz HM. Hospital patterns of use of positive inotropic agents in patients with heart failure. J Am Coll Cardiol. 2012;60:1402-1409.
13. LaBresh KA, Ellrodt AG, Gliklich R, Liljestrand J, Peto R. Get with the guidelines for cardiovascular secondary prevention: pilot results. Arch Intern Med. 2004;164:203-209.
14. Smaha LA; American Heart Association. The American Heart Association Get With The Guidelines program. Am Heart J. 2004;148(5 Suppl):S46-S48.
15. Fonarow GC, Abraham WT, Albert NM, Gattis WA, Gheorghiade M, Greenberg B, O'Connor CM, Yancy CW, Young J. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. Am Heart J. 2004;148:43-51.
16. Krumholz HM, Wang Y, Mattera JA, Wang Y, Han LF, Ingber MJ, Roman S, Normand SL. An administrative claims model suitable for profiling hospital performance based on 30-day mortality rates among patients with heart failure. Circulation. 2006;113:1693-1701.
17. Fonarow GC. Epidemiology and risk stratification in acute heart failure. Am Heart J. 2008;155:200-207.
18. Moineddin R, Matheson FI, Glazier RH. A simulation study of sample size for multilevel logistic regression models. BMC Med Res Methodol. 2007;7:34.
19. Team R. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2010.
20. Lasky T, Greenspan J, Ernst FR, Gonzalez L. Dopamine and dobutamine use in preterm or low birth weight neonates in the premier 2008 database. Clin Ther. 2011;33:2082-2088.
21. De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, Brasseur A, Defrance P, Gottignies P, Vincent JL; SOAP II Investigators. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362:779-789.